The pharmacogenetics of antimalaria artemisinin combination therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 10, 2011, Pages 1185-1200

  Piedade, Rita ^a,b   Gil, José Pedro ^a,b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c BINGHAMTON UNIVERSITY   (United States)

Author keywords

Amodiaquine; Artemisinin; Artemisinin combination therapy; Combination therapy; CYP2C8; CYP3A4; Malaria; Pharmacogenetics; Translational medicine

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; CHLOROQUINE; COARSUCAM; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PYRAMAX; PYRONARIDINE; UNCLASSIFIED DRUG; WINTHROP;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; AREA UNDER THE CURVE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EVIDENCE BASED MEDICINE; HUMAN; LIVER INJURY; MALARIA; MALARIA CONTROL; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PHARMACOGENETICS; REVIEW;

AMINOQUINOLINES; ANTIMALARIALS; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; EVIDENCE-BASED MEDICINE; FLUORENES; GENETIC MARKERS; HUMANS; MALARIA, FALCIPARUM; MEFLOQUINE; PHARMACOGENETICS; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE;

ARTESUNATE; PLASMODIUM FALCIPARUM;

EID: 80053031249     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.608660     Document Type: Review

References (126)

1. Marsh K. Malaria disaster in Africa. Lancet 1998;352(9132):924 (Pubitemid 28427275)
2. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009;7(12):864-74
3. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009;7(8):999-1013
4. Hsu E. Chinese propriety medicines: an "alternative modernity?" The case of the anti-malarial substance artemisinin in East Africa. Med Anthropol 2009;28(2):111-40
5. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J 2008;7(Suppl 1):S8
6. del Pilar Crespo M, Avery TD, Hanssen E, et al. Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob Agents Chemother 2008;52(1):98-109
7. Wang J, Huang L, Li J, et al. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010;5(3):e9582
8. Krishna S, Pulcini S, Fatih F, Staines H. Artemisinins and the biological basis for the PfATP6/ SERCA hypothesis. Trends Parasitol 2010;26(11):517-23
9. Wongsrichanalai C, Prajakwong S, Meshnick SR, et al. Mefloquine-its 20 years in the Thai Malaria Control Program. Southeast Asian J Trop Med Public Health 2004;35(2):300-8 (Pubitemid 39248705)
10. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000;356(9226):297- 302 (Pubitemid 30459588)
11. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007;77(6 Suppl):181-92
12. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999;41(1-3):301-8
13. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009(3):CD007483
14. DAlessandro U. Progress in the development of piperaquine combinations for the treatment of malaria. Curr Opin Infect Dis 2009;22(6):588-92
15. Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010;375(9724):1457-67
16. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007;4(11):e309
17. Greenwood B. Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas. Malar J 2010;9(Suppl 3):S2
18. Song J, Socheat D, Tan B, et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J 2010;9:57
19. Pang T. Impact of pharmacogenomics on neglected diseases of the developing world. Am J Pharmacogenomics 2003;3(6):393-8 (Pubitemid 38044279)
20. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE 2009;4(2):e4551
21. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359(24):2619-20
22. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361(5):455-67
23. Peters W. Chemotherapy and drug resistance in malaria. Academic Press; London, New York: 1970
24. Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 2005;182(4):181-5 (Pubitemid 40298186)
25. Teja-Isavadharm P, Watt G, Eamsila C, et al. Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 2001;65(6):717-21 (Pubitemid 34049461)
26. Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001;95(2):182-3 (Pubitemid 34947383)
27. Li XQ, Bjorkman A, Andersson TB, et al. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003;59(5-6):429-42 (Pubitemid 37214951)
28. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999;37(2):105-25
29. van Agtmael MA, Gupta V, van der Wosten TH, et al. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 1999;55(5):405-10 (Pubitemid 29344086)
30. Lefevre G, Carpenter P, Souppart C, et al. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002;54(5):485-92 (Pubitemid 35356874)
31. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116(3):496-526 (Pubitemid 350116943)
32. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10(5):373-88 (Pubitemid 30433571)
33. Ali S, Najmi MH, Tarning J, Lindegardh N. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Malar J 2010;9:275
34. Karunajeewa HA, Ilett KF, Dufall K, et al. Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother 2004;48(8):2966-72 (Pubitemid 38989162)
35. Ilett KF, Ethell BT, Maggs JL, et al. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2002;30(9):1005-12
36. Dien TK, de Vries PJ, Khanh NX, et al. Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob Agents Chemother 1997;41(5):1069-72 (Pubitemid 27194187)
37. Angus BJ, Thaiaporn I, Chanthapadith K, et al. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002;46(3):778-82 (Pubitemid 34157663)
38. Hien TT, Davis TM, Chuong LV, et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother 2004;48(11):4234-9 (Pubitemid 39434880)
39. Kerb R, Fux R, Morike K, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009;9(12):760-74
40. van Agtmael MA, Van Der Graaf CA, Dien TK, et al. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet 1998;23(3):429-36 (Pubitemid 28517733)
41. Na Bangchang K, Karbwang J, Thomas CG, et al. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J Clin Pharmacol 1994;37(3):249-53 (Pubitemid 24212184)
42. McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006;62(12):1021-31 (Pubitemid 44786494)
43. Lefevre G, Carpenter P, Souppart C, et al. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J Clin Pharmacol 2002;42(10):1147-58
44. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001;64(5-6):247-56
45. Mwesigwa J, Parikh S, McGee B, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 2010;54(1):52-9
46. Villeneuve L, Girard H, Fortier LC, et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10- hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003;307(1):117-28 (Pubitemid 37151897)
47. Mehlotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur J Clin Pharmacol 2007;63(1):1-8 (Pubitemid 46025467)
48. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009;10(7):754-80
49. Burckhalter JH, Tendick FH, et al. Aminoalkylphenols as antimalarials (heterocyclicamino)-alpha-amino-ocresols; the synthesis of camoquin. J Am Chem Soc 1948;70(4):1363-73
50. Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003(2):CD000016
51. Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986;1(8478):411-14 (Pubitemid 16166282)
52. Larrey D, Castot A, Pessayre D, et al. Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 1986;104(6):801-3 (Pubitemid 16115046)
53. Neftel KA, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986;292(6522):721-3 (Pubitemid 16167398)
54. Aymard JP, Rouveix B, Ferry R, et al. Amodiaquine-induced agranulocytosis: report of a case with in vitro studies of granulocyte- macrophage progenitor cells. Acta Haematol 1989;82(1):40-2 (Pubitemid 19223734)
55. WHO. World malaria report. World Health Organization; 2008
56. Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991;95(4):369-75
57. Naisbitt DJ, Ruscoe JE, Williams D, et al. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J Pharmacol Exp Ther 1997;280(2):884-93 (Pubitemid 27171352)
58. Jewell H, Maggs JL, Harrison AC, et al. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 1995;25(2):199-217
59. Tingle MD, Jewell H, Maggs JL, et al. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol 1995;50(7):1113-19
60. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27(1):25-61 (Pubitemid 38186936)
61. Gil JP. Amodiaquine pharmacogenetics. Pharmacogenomics 2008;9(10):1385-90
62. Harrison AC, Kitteringham NR, Clarke JB, Park BK. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol 1992;43(7):1421-30
63. Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 1987;23(1):1-7 (Pubitemid 17101817)
64. Li XQ, Bjorkman A, Andersson TB, et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002;300(2):399-407 (Pubitemid 34106229)
65. Churchill FC, Mount DL, Patchen LC, Bjorkman A. Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods. J Chromatogr 1986;377:307-18 (Pubitemid 16066388)
66. Zhang J, Krugliak M, Ginsburg H. The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. Mol Biochem Parasitol 1999;99(1):129-41 (Pubitemid 29127192)
67. Famin O, Ginsburg H. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Biochem Pharmacol 2002;63(3):393-8 (Pubitemid 34169719)
68. Gil JP, Gil Berglund E. CYP2C8 and antimalaria drug efficacy. Pharmacogenomics 2007;8(2):187-98
69. Johansson T, Jurva U, Gronberg G, et al. Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry, and NMR. Drug Metab Dispos 2009;37(3):571-9
70. Parikh S, Ouedraogo JB, Goldstein JA, et al. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007;82(2):197-203 (Pubitemid 47075331)
71. Singh R, Ting JG, Pan Y, et al. Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 2008;23(3):165-74
72. Hietala SF, Bhattarai A, Msellem M, et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 2007;34(5):669-86 (Pubitemid 47477038)
73. Mariga ST, Gil JP, Sisowath C, et al. Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2004;48(11):4089-96 (Pubitemid 39434860)
74. Hombhanje FW, Hwaihwanje I, Tsukahara T, et al. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol 2005;59(3):298-301 (Pubitemid 40388084)
75. Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. Am J Epidemiol 2005;161(10):901-15 (Pubitemid 40656412)
76. Davis TM, Hung TY, Sim IK, et al. Piperaquine: a resurgent antimalarial drug. Drugs 2005;65(1):75-87 (Pubitemid 40143802)
77. Tarning J, Bergqvist Y, Day NP, et al. Characterization of human urinary metabolites of the antimalarial piperaquine. Drug Metab Dispos 2006;34(12):2011-19 (Pubitemid 44837762)
78. Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004;57(3):253-62 (Pubitemid 38296988)
79. Chinh NT, Quang NN, Thanh NX, et al. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother 2009;53(2):828-31
80. Nguyen DV, Nguyen QP, Nguyen ND, et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother 2009;53(8):3534-7
81. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 2001;40(5):343-73 (Pubitemid 32565596)
82. Qi J, Wang S, Liu G, et al. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun 2004;319(4):1124-31 (Pubitemid 38759528)
83. Crowe A, Ilett KF, Karunajeewa HA, et al. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother 2006;50(10):3504-6 (Pubitemid 44527539)
84. Kim IW, Booth-Genthe C, Ambudkar SV. Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 2008;8(3):193-200 (Pubitemid 351611822)
85. Naisbitt DJ, Williams DP, ONeill PM, et al. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol 1998;11(12):1586-95 (Pubitemid 29013636)
86. Rohrbach P, Sanchez CP, Hayton K, et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. Embo J 2006;25(13):3000-11 (Pubitemid 44106753)
87. Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 2009;199(5):750-7
88. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990;19(4):264-79 (Pubitemid 20283426)
89. Na-Bangchang K, Karbwang J, Palacios PA, et al. Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 2000;55(10):743-8 (Pubitemid 30077570)
90. Ramharter M, Kurth FM, Belard S, et al. Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother 2007;60(5):1091-6 (Pubitemid 47617759)
91. Krudsood S, Looareesuwan S, Tangpukdee N, et al. New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. Antimicrob Agents Chemother 2010;54(9):3730-7
92. Karbwang J, Bunnag D, Breckenridge AM, Back DJ. The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. Eur J Clin Pharmacol 1987;32(2):173-7 (Pubitemid 17053293)
93. Karbwang J, Na-Bangchang K. Clinical application of mefloquine pharmacokinetics in the treatment of P. falciparum malaria. Fundam Clin Pharmacol 1994;8(6):491-502
94. Fontaine F, de Sousa G, Burcham PC, et al. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci 2000;66(22):2193-212 (Pubitemid 30313087)
95. German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008;47(2):91-102
96. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17 (Pubitemid 29222549)
97. Pham YT, Regina A, Farinotti R, et al. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta 2000;1524(2-3):212-19
98. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009;65(11):1063-70
99. Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009;7(1):2-6
100. Aarnoudse AL, van Schaik RH, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 2006;80(4):367-74 (Pubitemid 44479754)
101. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007;81(2):265-9 (Pubitemid 46174824)
102. Wu CP, Klokouzas A, Hladky SB, et al. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochem Pharmacol 2005;70(4):500-10 (Pubitemid 40978539)
103. Letourneau IJ, Deeley RG, Cole SP. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 2005;15(9):647-57 (Pubitemid 41113337)
104. Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J 2009;8(Suppl 1):S4
105. Noedl H, Allmendinger T, Prajakwong S, et al. Desbutylbenflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand. Antimicrob Agents Chemother 2001;45(7):2106-9 (Pubitemid 32591705)
106. Starzengruber P, Wernsdorfer G, Parizek M, et al. Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. Wien Klin Wochenschr 2007;119(19-20 Suppl 3):60-6 (Pubitemid 350094907)
107. Wong RP, Salman S, Ilett KF, et al. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother 2011;55(3):1194-8
108. Denis MB, Tsuyuoka R, Lim P, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 2006;11(12):1800-7 (Pubitemid 44813874)
109. Rahman MM, Dondorp AM, Day NP, et al. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg 2008;102(9):861-7
110. Borrmann S, Sallas WM, Machevo S, et al. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010;15(4):434-41
111. Wernsdorfer WH. Coartemether (artemether and lumefantrine): an oral antimalarial drug. Expert Rev Anti Infect Ther 2004;2(2):181-96 (Pubitemid 38735763)
112. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics 2009;10(8):1323-39
113. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009;61(5):541-58
114. Westlind-Johnsson A, Hermann R, Huennemeyer A, et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006;79(4):339-49
115. Na-Bangchang K, Ruengweerayut R, Mahamad P, et al. Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. Malar J 2010;9:273
116. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004;364(9432):438-47 (Pubitemid 39036891)
117. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005;191(6):1014-17 (Pubitemid 40349821)
118. Holmgren G, Hamrin J, Svard J, et al. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol 2007;7(5):562-9 (Pubitemid 47338282)
119. Echeverry DF, Holmgren G, Murillo C, et al. Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Am J Trop Med Hyg 2007;77(6):1034-8 (Pubitemid 351837788)
120. Cavaco I, Stromberg-Norklit J, Kaneko A, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 2005;61(1):15-18 (Pubitemid 40558274)
121. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32(6):647-60 (Pubitemid 38668158)
122. Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet 2010;376(9742):739-41
123. Ferreira P CI, Gil JP. Pharmacogenetic tools for malaria and TB in the developing world. Pers Med 2008;5(6):627-39
124. Ishengoma DS, Lwitiho S, Madebe RA, et al. Using rapid diagnostic tests as source of malaria parasite DNA for molecular analyses in the era of declining malaria prevalence. Malar J 2011;10(1):6
125. Nosten F, Brasseur P. Combination therapy : the way forward? Drugs 2002;62(9):1315-29
126. Available from: http:/http://www. cypalleles.ki.se